Author

Marco Mernberger

Philipps University of Marburg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Andrea NistiD· 2 shared Daniel SpeideliD· 2 shared Florian Rothweiler· 2 shared Martin MichaelisiD· 2 shared Thorsten StieweiD· 2 shared Andreas von Deimling· 1 shared Catherine L. Harper-WynneiD· 1 shared Constanze Schneider· 1 shared

Activity by Year

2018-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrea NistORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer LettersPeer-reviewedApr 27, 2025

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

Helen E. Grimsley, Magdalena Antczak, Ian G. Reddin…·Martin Michaelis

This study identifies drug-resistant sublines of TNBC cell lines and finds that resistance mechanisms are unique and unpredictable, suggesting new potential drug targets.

9 citations

humanwhole-exome sequencing

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintAug 30, 2018

TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance

Martin Michaelis, Constanze Schneider, Florian Rothweiler…·Jindrich Cinatl

This study establishes MDM2 inhibitor-resistant AML sub-lines and finds that resistance arises from pre-existing TP53 mutations or de novo mutations, with variable drug sensitivity despite loss of p53 function.

DOI 10.1101/404475

humanbulk RNA-seq

𝕏 PostBluesky